Simplify Genomics

Tech-enabled platform turning genomic data into actionable healthcare solutions

wefunder

Simplify Genomics is a health technology company focused on enabling clinical action from whole-genome sequencing. It originated in 2016 under Human Longevity, the venture founded by Craig Venter, and was spun out in 2022. Human Longevity continues to rely on Simplify Genomics reports to guide its Longevity Program, grounded in prior development funding of over $90 million.

The company’s flagship platform, Smart Genome, is an automated genome reporting system designed for scale to bring practical clinical use to deep genomic data. It comprises three components: Simplify Genome, a CLIA-certified and CAP-accredited dry laboratory that delivers actionable insights from whole-genome sequencing with AI-informed, explainable content; Simplify Search, an AI-driven genome exploration platform that provides rapid access to raw genetic data, clinical information, and the latest genomic insights; and Simplify Data, a multi-source data repository aggregating public, proprietary, and clinical data to support discovery and research.

Since 2018, the platform has curated over 7,000 genes and millions of variants, producing more than 10,000 clinically actionable whole-genome reports. The technology stack supports rapid, scalable interpretation of genomic data, with frequent content updates and ongoing development across versions.

The platform maintains a large genomic database, including more than 35,000 whole genomes and 400 million unique variants, alongside a curated set of 1.6 million variants linked to diseases and risk assessments. The technology aims to reduce reliance on manual interpretation and accelerate the delivery of clinically relevant genomic insights.

Historically, revenue has been generated primarily from Human Longevity, with annual revenue in the low-to-mid millions. The target market includes concierge medicine and executive health, where the reports augment current offerings with genomic context to differentiate services. The company envisions expansion into additional markets as adoption grows and additional monetization streams emerge, including broader access to the search and data platforms and potential subscription models.

The team comprises veterans from the health tech sector, including a leadership group previously involved with Human Longevity and Craig Venter, and the CEO, Travis Lacey, who has a background in business and previously built a genomics platform later acquired by NeoGenomics Laboratories. The company notes precedent acquisitions in the healthcare technology sector as context for potential strategic opportunities.

Travis Lacey

Co-Founder and CEO

Wayne Delport

Co-Founder and Chief Technology Officer

In 1H 2025, Simplify Genomics onboarded four new concierge clients and received ~850 report orders, up 15% versus the prior six months. The company signed a commercial contract for research on a client’s genomic data, granted beta access to its Simplify Search platform, and rescheduled an MRI center integration partnership from Q3 to Q4 2025 to validate saliva collection. Operationally, it is validating saliva as a specimen type (completion anticipated in Q4 2025), expanding its Simplify Genome report to 3,000+ annotated genes by end of Q4 2025, targeting a 20% reduction in cost of goods while targeting 60%+ gross margins, and preparing for a biannual CAP inspection later in 2025.

Simplify Genomics 1H 2025 investor update: orders up 15%, new clients and contracts, partnerships pushed to Q4

Simplify Genomics says its investors helped the company raise $5 million to advance genomic diagnostics and it will work with O’Ryan Health to broaden access to testing. The update claims O’Ryan Health’s Artemis Platform has collected over 130 pediatric blood samples in four months, generated about 1 terabyte of pediatric research data, achieved a 99% satisfaction rate, and received IRB Umbrella Protocol approval to serve families across the lower 48 states.